The Autoantibody Array Assay: A Novel Autoantibody Detection Method

Yuta Norimatsu, Kazuki Matsuda, Kei Yamaguchi, Chihiro Ono, Taishi Okumura, Emi Kogo, Hirohito Kotani, Teruyoshi Hisamoto, Ai Kuzumi, Takemichi Fukasawa, Asako Yoshizaki‐Ogawa, Naoki Goshima, Shinichi Sato, Ayumi YoshizakiDiagnostics 2023 · DOI

TL;DR

This paper introduces "A-cube," a novel autoantibody detection method utilizing wheat germ cell-free protein synthesis. A-cube demonstrates comparable or superior sensitivity and specificity to existing methods for diagnosing Systemic Sclerosis (SSc) and Dermatomyositis (DM), even detecting antibodies missed by conventional techniques, potentially improving clinical assessment and diagnosis.

What Problem Does This Paper Address?

Diagnosing and monitoring autoimmune collagen diseases like Systemic Sclerosis (SSc) and Dermatomyositis (DM) relies heavily on detecting specific autoantibodies. While immunoprecipitation is the gold standard, its use of radioisotopes makes it impractical for routine clinical use. Existing alternatives like immunoblotting and ELISA have limitations, including high false-negative rates, particularly for certain antibodies like anti-Jo-1. Furthermore, the complex nature of some autoantigens, like the aminoacyl-tRNA synthetase complex, poses challenges for traditional synthesis methods, hindering accurate detection. This gap necessitates a more accessible, sensitive, and comprehensive method for autoantibody profiling in SSc and DM.

Methods

The core innovation is the "A-cube" assay, which leverages wheat germ cell-free protein synthesis. This technique allows for the production of complex proteins with their higher-order structures preserved, which is crucial for accurate antibody recognition.

Here's a breakdown of the methodology:

  • Protein Synthesis: Wheat germ cell-free protein synthesis was employed to produce target autoantigens. This method is highlighted for its ability to express proteins of various molecular weights and maintain their native conformation, unlike prokaryotic systems like E. coli.
  • Array Plate Preparation: Synthesized FLAG-GST-tagged proteins were captured onto amino-group-modified glass array plates. The plates were prepared and stored under conditions designed to maintain protein integrity.
  • Assay Procedure: Patient sera were incubated with the array plates. Binding of autoantibodies to the immobilized antigens was detected.
  • Comparison with Existing Methods: The A-cube assay's performance was validated by comparing its results against established diagnostic methods, including ELISA and immunoprecipitation, for a range of SSc and DM-associated autoantibodies.
  • Statistical Analysis: Spearman's rank correlation test was used to assess the correlation between A-cube results and existing test results, with statistical significance set at p < 0.05.

Datasets

  • Patient Cohorts:
    • 100 patients diagnosed with Systemic Sclerosis (SSc) based on the 2013 American College of Rheumatology (ACR) criteria.
  • 50 patients diagnosed with Dermatomyositis (DM) based on the 2017 EULAR/ACR criteria.
  • 82 healthy control participants.
  • Exclusion Criteria: Serum from patients suffering from infectious diseases was excluded.
  • Control Sera: Sera from patients with benign skin tumors who visited the dermatology department and provided consent were used as controls.

Key Insights and Ideas

  • Preserving Protein Structure is Key: The wheat germ cell-free system's ability to maintain the higher-order structure of synthesized proteins, particularly for complex enzyme complexes like those involved in anti-OJ antibodies, is critical for accurate autoantibody detection. This suggests that the native conformation of an antigen is paramount for reliable antibody binding.
  • A-cube's Potential for Undetected Antibodies: The A-cube assay successfully detected anti-OJ antibodies that were missed by conventional methods, highlighting its superior sensitivity for certain challenging targets. This opens doors for diagnosing conditions previously difficult to pinpoint.
  • Revisiting Diagnoses: The A-cube assay facilitated the reconsideration of diagnoses in some cases, particularly in differentiating between SSc and DM, or identifying overlap syndromes. This underscores the value of a comprehensive autoantibody profile for complex autoimmune presentations.
  • Beyond Specificity: Comprehensive Profiling: The study suggests that a comprehensive analysis of autoantibodies, rather than focusing on individual markers, can provide a more nuanced understanding of SSc and DM, potentially clarifying antibody profile characteristics that vary geographically.

Key Results

  • Comparable or Superior Performance: The A-cube assay demonstrated comparable or high sensitivity and specificity when compared to existing testing methods for a range of SSc and DM autoantibodies.
  • High Concordance: For many antibodies tested, the A-cube showed high concordance rates with existing tests. For example, anti-centromere antibodies showed a 100% concordance rate with ELISA.
  • Detection of Previously Undetected Antibodies: The A-cube was able to detect anti-OJ antibodies that could not be identified by conventional tests, including those missed by immunoprecipitation.
  • Correlation with Existing Tests: Strong correlations were observed between autoantibody titers measured by A-cube and those measured by existing methods (e.g., anti-centromere antibodies: p < 0.0001, r = 0.9421; anti-topoisomerase I: p < 0.0001, r = 0.906; anti-RNA polymerase III: p = 0.0001, r = 0.934).
  • Diagnostic Reconsideration: In one instance, the A-cube assay led to a reconsideration of a patient's diagnosis, suggesting its utility in clarifying complex cases.
  • Immunoprecipitation Comparison: The A-cube detected antibodies detected by immunoprecipitation in 60 out of 61 cases, with the exception of anti-TIF1ß antibody.

Limitations and Future Work

  • Limitations:
    • The paper notes that 100% specificity was not achieved for all antibodies in healthy participants, which is considered a natural result given the known presence of some autoantibodies in healthy individuals.
  • There were instances of discordance between A-cube and existing tests, which were often attributed to potential false positives or negatives in the existing methods (e.g., ELISA).
  • The anti-TIF1ß antibody was not detected by A-cube when it was detected by immunoprecipitation.
  • Future Work:
    • The authors suggest that a comprehensive analysis using A-cube may clarify the characteristics of antibody profiles in SSc, which are known to vary geographically.
  • They propose that A-cube could enable more accurate diagnosis of SSc or DM in cases that only meet early diagnostic criteria, which are currently difficult to diagnose with existing tests.
  • The study highlights the potential of A-cube for facilitating differentiation between SSc and DM, which can be challenging.
  • The authors believe A-cube can become a useful diagnostic tool for both SSc specialists and non-specialists.

Summary updated

Abstract

Systemic sclerosis (SSc) and dermatomyositis (DM) are autoimmune collagen diseases. Specific autoantibodies are known to be involved in their pathogeneses, each presenting with a different clinical manifestation. Although immunoprecipitation is the gold standard method for detecting autoantibodies, it is difficult to perform in all cases owing to the use of radioisotopes. In this study, we developed a new detection method for SSc and DM autoantibodies (A-cube) using cell-free protein synthesis and examined its validity. Proteins were synthesized using wheat germ cell-free protein synthesis. A total of 100 cases of SSc, 50 cases of DM, and 82 healthy controls were examined. The validity of the method was examined by a comparison with existing test results. Anti-centromere antibody, anti-topoisomerase I antibody, anti-RNA polymerase III antibody, anti-U1RNP anti-body, anti-Jo-1 antibody, anti-TIF1γ antibody, anti-Mi-2 antibody, and anti-ARS antibody were tested for. The results suggested that A-cube is comparable with existing testing methods or has a high sensitivity or specificity. In addition, there was a case in which the diagnosis was reconsidered using the A-cube. The quality of the A-cube was ensured, and its usefulness for a comprehensive analysis was demonstrated. The A-cube can therefore contribute to the clinical assessment and treatment of SSc and DM.
BibTeX
@inproceedings{norimatsu2023autoantibody,
  author = {Yuta Norimatsu and Kazuki Matsuda and Kei Yamaguchi and Chihiro Ono and Taishi Okumura and Emi Kogo and Hirohito Kotani and Teruyoshi Hisamoto and Ai Kuzumi and Takemichi Fukasawa and Asako Yoshizaki‐Ogawa and Naoki Goshima and Shinichi Sato and Ayumi Yoshizaki},
  title = {{The Autoantibody Array Assay: A Novel Autoantibody Detection Method}},
  booktitle = {Diagnostics},
  year = {2023},
  doi = {10.3390/diagnostics13182929},
}
Figure